Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Stefania Russo
Institutions:
Ospedale Santa Maria della Misericordia di Udine,
Azienda sanitaria universitaria Friuli Centrale
Observed institutions:
Ospedale Santa Maria della Misericordia di Udine,
Azienda sanitaria universitaria Friuli Centrale
ORCID:
0009-0002-0221-4152
Observed ORCID:
0009-0002-0221-4152
OpenAlex ID:
A5048548720
The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
2024
·
Matteo Dugo
, Chiun-Sheng Huang
, et al.
·
Clinical Cancer Research
·
31
PDF
Abstract P2-07-12: Triple negative breast cancer subtypes and early dynamics of the 27-gene IO score predict pCR in the NeoTRIPaPDL1 trial
2022
·
Matteo Dugo
, Chiun-Sheng Huang
, et al.
·
Cancer Research
·
7
Abstract PD10-06: Predictive value of RT-qPCR 27-gene IO score and comparison with RNA-Seq IO score in the NeoTRIPaPDL1 trial
2022
·
Matteo Dugo
, Chiun-Sheng Huang
, et al.
·
Cancer Research
·
7
Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative breast cancer
2025
·
Justin M. Balko
, Luca Licata
, et al.
·
npj Breast Cancer
·
4
PDF
Analysis of event-free survival (EFS) of stromal tumor infiltrating lymphocytes (sTILs), PD-L1 expression, and their early dynamics in the NeoTRIP trial.
2025
·
Giampaolo Bianchini
, Giulia Viale
, et al.
·
Journal of Clinical Oncology
·
2
Data from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
2024
·
Matteo Dugo
, Chiun-Sheng Huang
, et al.
·
1
Supplementary Data S1 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
2024
·
Matteo Dugo
, Chiun-Sheng Huang
, et al.
Supplementary Figure S3 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
2024
·
Matteo Dugo
, Chiun-Sheng Huang
, et al.
Supplementary Figure S1 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
2024
·
Matteo Dugo
, Chiun-Sheng Huang
, et al.
Supplementary Figure S4 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
2024
·
Matteo Dugo
, Chiun-Sheng Huang
, et al.
Supplementary Figure S2 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
2024
·
Matteo Dugo
, Chiun-Sheng Huang
, et al.
Supplementary Figure S6 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
2024
·
Matteo Dugo
, Chiun-Sheng Huang
, et al.
Supplementary Table S4 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
2024
·
Matteo Dugo
, Chiun-Sheng Huang
, et al.
Supplementary Figure S5 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
2024
·
Matteo Dugo
, Chiun-Sheng Huang
, et al.
Supplementary Table S3 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
2024
·
Matteo Dugo
, Chiun-Sheng Huang
, et al.
Supplementary Table S5 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
2024
·
Matteo Dugo
, Chiun-Sheng Huang
, et al.
Supplementary Figure S7 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
2024
·
Matteo Dugo
, Chiun-Sheng Huang
, et al.
Supplementary Table S1 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
2024
·
Matteo Dugo
, Chiun-Sheng Huang
, et al.
Supplementary Table S2 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
2024
·
Matteo Dugo
, Chiun-Sheng Huang
, et al.
Show more works
View as search
Works count:
19
Citation count:
52
H-index:
4
I10-index:
1
Year
Topic
Type